Multivalent Vaccines Market Report 2026

Multivalent Vaccines Market Overview

• Multivalent Vaccines market size has reached to $9.12 billion in 2025 • Expected to grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Infectious Disease Incidences Drive Growth In The Multivalent Vaccine Market • Market Trend: Advancements In Pentavalent Vaccines Enhance Efficiency And Sustainability In Immunization • North America was the largest region in 2025.

What Is Covered Under Multivalent Vaccines Market?

Multivalent vaccines are vaccines designed to protect against multiple strains or types of a single pathogen, or against several different pathogens, in a single dose. By including antigens from various strains or diseases, these vaccines generate immunity against several targets simultaneously, offering broader protection compared to monovalent vaccines, which focus on a single strain or pathogen. The main types of multivalent vaccines are conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines link a weaker antigen to a stronger one, enhancing immune recognition and effectiveness, particularly for bacterial diseases. These are used for various diseases such as influenza, pneumonia, hepatitis, meningitis, and rotavirus, and they are administered through different routes, including oral and injectable. It is provided to several age groups, such as pediatrics, adults, and geriatrics, and sold through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Multivalent Vaccines Market Growth Forecast?

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising focus on pandemic preparedness, increasing elderly population, growth in recombinant vaccine technologies, expansion of universal immunization coverage, increased healthcare funding. Major trends in the forecast period include rising demand for broad-spectrum immunization, increasing focus on combination vaccines, expansion of pediatric and geriatric vaccination programs, growing adoption of preventive healthcare measures, higher investment in vaccine r&d pipelines.

Global Multivalent Vaccines Market Segmentation

1) By Type: Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines 2) By Disease: Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus 3) By Route Of Administration: Oral, Injectable 4) By Age Group: Pediatrics, Adults, Geriatrics 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines, Protein Conjugate Vaccines 2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines, Subunit Protein Vaccines, Virus-Like Particle Vaccines 3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines, Live Attenuated Viral Vaccines 4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines 5) By Recombinant Vaccines: Recombinant Protein Vaccines, Recombinant DNA Vaccines

What Is The Driver Of The Multivalent Vaccines Market?

The rising incidences of infectious diseases are expected to propel the growth of the multivalent vaccines market going forward. Infectious diseases refer to illnesses caused by bacteria, viruses, fungi, or parasites that can spread through direct contact, contaminated surfaces, air, or water. The rising incidence of infectious diseases is driven by increased global travel, which accelerates the movement of pathogens across borders. The multivalent vaccines market supports disease prevention by offering vaccines that target multiple pathogen strains in a single dose, reducing the need for separate immunizations and strengthening herd immunity. For instance, in April 2024, according to TravelHealthPro, a UK-based travel health resource supported by the UK Health Security Agency, the UK recorded 2,004 malaria cases in 2023, up from 1,369 imported cases in 2022. Therefore, the rising incidences of infectious diseases are driving the growth of the multivalent vaccines industry.

Key Players In The Global Multivalent Vaccines Market

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Novartis AG, CSL Seqirus, Zydus Lifesciences Limited, Sinovac Biotech Ltd., GC Biopharma Corp., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., VBI Vaccines Inc., WestVac Biopharma Co. Ltd., Emergent BioSolutions Inc., Moderna Inc., BioNTech SE, Abbott Laboratories, Boehringer Ingelheim International GmbH

Global Multivalent Vaccines Market Trends and Insights

Major companies operating in the multivalent vaccines market are focusing on developing advanced pentavalent vaccines to expand immunization coverage, simplify dosing schedules, and improve overall public health outcomes. Pentavalent vaccines refer to multivalent formulations designed to provide protection against five distinct pathogens in a single dose, reducing the number of injections required, improving compliance, and streamlining vaccine delivery programs. For instance, in December 2023, Panacea Biotec Ltd., an India-based biotechnology company, launched EasyFourPol, the world’s first fully liquid pentavalent vaccine that protects against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae Type B, featuring a ready-to-use formulation that eliminates preparation steps for healthcare workers, reduces the number of clinic visits and associated immunization costs, and minimizes environmental impact by lowering the need for multiple vials, syringes, and packaging materials.

What Are Latest Mergers And Acquisitions In The Multivalent Vaccines Market?

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition strengthens AstraZeneca’s vaccine portfolio by adding Icosavax’s late-stage RSV candidate, IVX-A12, and expands the company’s presence in the respiratory vaccine market. It further enhances AstraZeneca’s development capabilities through Icosavax’s proprietary protein virus-like particle (VLP) platform, enabling the creation of multivalent vaccines for respiratory viruses. Icosavax Inc. is a US-based biotechnology company specializing in a protein VLP platform for multivalent vaccine development.

Regional Insights

North America was the largest region in the multivalent vaccines market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multivalent Vaccines Market?

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Multivalent Vaccines Market Report 2026?

The multivalent vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.